SCHEMBL704683

SCHEMBL704683

[2H]C(=O)c1ccc(OC([2H])([2H])[2H])c(OC([2H])([2H])C([2H])([2H])[2H])c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
TSHR P16473 1/20 0.40
FDPS P14324 2/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
PDCD1 Q15116 1/20 0.36
CD274 Q9NZQ7 1/20 0.36
NFE2L2 Q16236 1/20 0.34
TUBB1 Q9H4B7 2/20 0.33
PDE4B Q07343 1/20 0.33
DYRK1A Q13627 1/20 0.33
PDE3A Q14432 1/20 0.33
KDM4E B2RXH2 2/20 0.33
APP P05067 1/20 0.33
CA12 O43570 2/20 0.32
CA1 P00915 2/20 0.32
CA2 P00918 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL702720 0.90 ALDH1A1 (0.53) ALDH1A1TSHRFDPSSMN1; SMN2LMNA
3,4-Dimethoxybenzaldehyde SCHEMBL2529644 0.84 ALDH1A1 (0.55) ALDH1A1TSHRFDPSSMN1; SMN2LMNA
SCHEMBL701781 0.82 ALDH1A1 (0.64) ALDH1A1TSHRFDPSSMN1; SMN2LMNA
SCHEMBL10029177 0.76 CA2 (0.37) ALDH1A1MAPTHTTTUBB1KDM4E
SCHEMBL703866 0.74 ALDH1A1 (0.62) ALDH1A1TSHRFDPSSMN1; SMN2LMNA
3,4-Dimethoxybenzaldehyde SCHEMBL2370925 0.72 ALDH1A1 (0.74) ALDH1A1TSHRFDPSSMN1; SMN2LMNA
3,4-Dimethoxybenzaldehyde SCHEMBL13290624 0.69 ALDH1A1 (0.81) ALDH1A1TSHRFDPSSMN1; SMN2LMNA
3,4-Dimethoxybenzaldehyde SCHEMBL2370931 0.69 ALDH1A1 (0.81) ALDH1A1TSHRFDPSSMN1; SMN2LMNA
SCHEMBL10029176 0.66 PDE4B (0.38) PDE4BCA1CA2
SCHEMBL30028779 0.63 ALDH1A1 (0.61) ALDH1A1FDPSSMN1; SMN2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264524-A1 SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES CONCERT PHARMACEUTICALS INC (US) 2016-09-15 US disclosed
US-9296689-B2 Substituted isoindoline-1,3-dione derivatives CONCERT PHARMACEUTICALS, INC. (US) 2016-03-29 US disclosed
US-20150105438-A1 SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES CONCERT PHARMACEUTICALS, INC. (US) 2015-04-16 US disclosed
US-8883843-B2 Substituted isoindoline-1,3-dione derivatives CONCERT PHARMACEUTICALS, INC. (US) 2014-11-11 US disclosed
US-20130345282-A1 SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES CONCERT PHARMACEUTICALS, INC. (US) 2013-12-26 US disclosed
US-8404737-B2 Substituted isoindoline-1,3-dione derivatives CONCERT PHARMACEUTICALS, INC. (US) 2013-03-26 US disclosed
US-8404737-B2 Substituted isoindoline-1,3-dione derivatives CONCERT PHARMACEUTICALS, INC. (US) 2013-03-26 US disclosed
US-20120252864-A1 SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES CONCERT PHARMACEUTICALS INC. 2012-10-04 US disclosed
US-20120252864-A1 SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES CONCERT PHARMACEUTICALS INC. 2012-10-04 US disclosed
US-8124646-B2 Substituted isoindoline-1,3-dione derivatives CONCERT PHARMACEUTICALS, INC. (US) 2012-02-28 US disclosed
US-8124646-B2 Substituted isoindoline-1,3-dione derivatives CONCERT PHARMACEUTICALS, INC. (US) 2012-02-28 US disclosed
US-20100324108-A1 SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES CONCERT PHARMACEUTICALS INC. 2010-12-23 US disclosed
US-20100324108-A1 SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES CONCERT PHARMACEUTICALS INC. 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130345282-A1 SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES QDPR, IDO1, ADRA1D ALDH1A1 4/4885TSHR 4771/4885FDPS 173/4885
US-20120252864-A1 SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES QDPR, IDO1, ADRA1D ALDH1A1 4/4885TSHR 4771/4885FDPS 173/4885
US-20160264524-A1 SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES QDPR, IDO1, ADRA1D ALDH1A1 4/4885TSHR 4771/4885FDPS 173/4885
US-20150105438-A1 SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES QDPR, IDO1, ADRA1D ALDH1A1 4/4885TSHR 4771/4885FDPS 173/4885
US-20100324108-A1 SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES QDPR, IDO1, ADRA1D ALDH1A1 4/4885TSHR 4771/4885FDPS 173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.